T-Cell receptors therapy is a growing area of immuno-oncology with recent breakthroughs in clinical settings, thereby demonstrating its therapeutic potential in mitigating tumor development. So what do you know about T-Cell therapy? Read on! Dr. Erika von Euw from T-Cure Bioscience help us to understand it better.
Cancer immunotherapy is a validated and critically important approach for treating cancer and offering hope for curative responses in patients. Cancer immunotherapy relies on genetically engineered T-cells. T Cell Receptor Therapy (TCR-T) is a growing area of immuno-oncology with recent breakthroughs in clinical settings, thereby demonstrating his therapeutic potential in mitigating tumor development.
Earlier this month, Atlas Antibodies signed a collaboration agreement with T-Cure Biosciences Inc. for the development, manufacture, and supply of PrecisA Monoclonals for the treatment of solid tumors. T-Cure is developing TCR-T therapeutics targeting the Kita-Kyushu Lung Cancer Antigen 1 (KK-LC-1) for gastric, triple-negative breast cancer, cervical, lung, and other KK-LC-1 positive cancers. Under the terms of the agreement, Atlas Antibodies will provide the KK-LC-1 PrecisA monoclonal antibody for the companion diagnostic for clinical development.
Read the press release: Atlas Antibodies & T-Cure Bioscience